Free Trial

Guardant Health Q1 2024 Earnings Report

Guardant Health logo
$31.67 +0.54 (+1.73%)
(As of 12/20/2024 05:16 PM ET)

Guardant Health EPS Results

Actual EPS
-$0.94
Consensus EPS
-$0.94
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Guardant Health Revenue Results

Actual Revenue
$168.49 million
Expected Revenue
$150.51 million
Beat/Miss
Beat by +$17.98 million
YoY Revenue Growth
N/A

Guardant Health Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today! (Ad)

Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.

>> You can grab your FREE, laminated copies right here << 

Guardant Health Earnings Headlines

This Indicator called BOTH NVDA rallies
Rarely would I label something as “the best” But in this rare instance, I believe this is THE BEST indicator for trading Nvida’s stock. Except, it’s not another tech stock like Nvidia. But rather a stock hiding in broad daylight… So, if you’d like to see what this stock is…
Guardant Health announces collaboration with Boehringer Ingelheim
See More Guardant Health Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Guardant Health? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Guardant Health and other key companies, straight to your email.

About Guardant Health

Guardant Health (NASDAQ:GH), a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

View Guardant Health Profile

More Earnings Resources from MarketBeat

Upcoming Earnings